DURECT Corporation (DRRX): Price and Financial Metrics

DURECT Corporation (DRRX): $0.83

0.03 (+3.11%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add DRRX to Watchlist
Sign Up

DRRX Price/Volume Stats

Current price $0.83 52-week high $7.46
Prev. close $0.81 52-week low $0.47
Day low $0.80 Volume 13,047
Day high $0.84 Avg. volume 188,578
50-day MA $1.02 Dividend yield N/A
200-day MA $1.78 Market Cap 25.76M

DRRX Stock Price Chart Interactive Chart >


DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.


DRRX Latest News Stream


Event/Time News Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about DURECT CORP that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

Q3 2023 DURECT Corp Earnings Call

Q3 2023 DURECT Corp Earnings Call

Yahoo | November 14, 2023

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2023 and provided a corporate update.

Yahoo | November 13, 2023

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 13, 2023

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call and webcast with investors to discuss financial results and provide a corpor

Yahoo | November 9, 2023

Cantor Fitzgerald Is Souring on Lucid Motors (LCID) Stock

Lucid Motors stock is falling after Cantor Fitzgerald analysts downgraded LCID shares and cut their price target following its Q3 earnings.

William White on InvestorPlace | November 8, 2023

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo -29.06%
3-mo 1.87%
6-mo -64.53%
1-year -81.26%
3-year -95.31%
5-year -85.08%
YTD 40.68%
2023 -82.95%
2022 -64.91%
2021 -52.37%
2020 -45.53%
2019 691.67%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!